Clinical Trials Logo

Clinical Trial Summary

Epidural analgesia is the gold standard of pain relief for labour pain. Despite this, more than 50% of parturients continue to experience pain leading to suffering and increased caregiver workload. Women who have increased pain tend to have lower successful patient bolus demands when patient controlled epidural analgesia (PCEA) is utilised and have dysfunctional labour requiring obstetric intervention such as Caesarean or instrumental delivery. Labour pain often escalates and worsens as labour progresses requiring an individualized, variable, flexible analgesic regimen. Bolus epidural administrations have been shown to improve uniform spread of local anaesthetics with better pain relief, compared to fixed background infusions.


Clinical Trial Description

The research team developed two novel epidural delivery regimens: computer-integrated PCEA (CIPCEA) and modified programmed intermittent bolus (MPIB) focused on individualization of analgesic requirements. This phase 3 double-blinded randomized controlled trial will compare the two novel regimens, and each with conventional PCEA with basal infusion (BI), in reducing breakthrough pain (failure of the regimen to provide adequate pain relief, necessitating unscheduled epidural supplementation) incidence as the primary outcome in nulliparous term women requesting labour epidural analgesia. In addition, a discrete choice experiment (DCE) in the format of a survey will be administered to estimate the women's preferences in treatment attributes related to epidural analgesia, including control over epidural dosage, chance of having breakthrough pain, motor block, instrumental delivery and out-of-pocket cost for epidural analgesia. We will also look into the association model for breakthrough pain that would take into account pre-delivery factors to better understand the mechanism of breakthrough pain during labor process. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02278601
Study type Interventional
Source KK Women's and Children's Hospital
Contact
Status Active, not recruiting
Phase Phase 3
Start date January 28, 2015
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Completed NCT00994760 - Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years N/A
Not yet recruiting NCT05531422 - Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP Phase 2
Completed NCT01842893 - Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer Phase 3
Completed NCT02886286 - Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain Phase 4
Completed NCT02869321 - Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Phase 4
Completed NCT02840500 - Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units N/A
Completed NCT02437929 - Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment N/A
Completed NCT00236145 - Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain Phase 3
Completed NCT02836379 - Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent N/A
Terminated NCT00842829 - Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients Phase 4
Recruiting NCT05200806 - A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy Phase 4
Withdrawn NCT03809455 - Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients Phase 2
Completed NCT03435120 - Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)
Completed NCT02050503 - Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal Mucositis N/A
Terminated NCT00387010 - Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain Phase 3
Withdrawn NCT05053308 - Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement N/A
Recruiting NCT04011150 - Development of Variable Volume Automated Mandatory Boluses for Patient-controlled Epidural Analgesia During Labour Phase 3
Terminated NCT01901718 - An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray. N/A
Completed NCT00402350 - Staccato Fentanyl Single and Multidose PK Phase 1
Completed NCT00236041 - Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP) Phase 2